Albireo Pharma, Inc. (ALBO) News
Filter ALBO News Items
ALBO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ALBO News Highlights
- ALBO's 30 day story count now stands at 3.
- Over the past 15 days, the trend for ALBO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about ALBO are DRUG, BEAT and LNTH.
Latest ALBO News From Around the Web
Below are the latest news stories about ALBIREO PHARMA INC that investors may wish to consider to help them evaluate ALBO as an investment opportunity.
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: Should You Buy?Mirum Pharmaceuticals, Inc. (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Is Albireo Pharma (ALBO) Stock Outpacing Its Medical Peers This Year?Here is how Albireo Pharma (ALBO) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year. |
FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille SyndromeBylvay (odevixibat) granted Priority Review by U.S. FDAASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhea rate in Alagille patientsApproval in second indication would more than double Bylvay market opportunity BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced that the U.S. Food and Drug |
Why These Two Biotech Stocks Blasted Higher This WeekTwo somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca, while Albireo Pharma (NASDAQ: ALBO) is set to be owned by France-based peer Ipsen. Both of these deals are very lucrative, to the point where CinCor's stock rocketed 146% over the course of the week, and Albireo shot 92% skyward, according to data compiled by S&P Global Market Intelligence. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning! |
JPMorgan Health Conference Kicks Off With Predictable Flurry of (Small) DealsThe annual JPMorgan Healthcare Conference in San Francisco, which kicked off today, is often a magnet for deal announcements. This year was no exception, though they were all of the smaller variety — mostly European drug companies paying big premiums to fill their pipelines. Among them, AstraZeneca PLC’s announcement that it would purchase CinCor Pharma Inc. for [as much as $1.8 billion](https://www.wsj.com/livecoverage/stock-market-news-today-01-09-2023/card/astrazeneca-to-buy-u-s-drugmaker-cin |
Ipsen to buy liver disease drugmaker for $952MIpsen is set to acquire Albireo Pharma Inc., the rare liver disease-focused biopharma spun out of AstraZeneca in 2008, for about $952 million. |
2 Tiny Nasdaq Stocks Making Major Merger Moves MondayThe Nasdaq Composite (NASDAQINDEX: ^IXIC) might finally be looking to gain some momentum in 2023, with investors desperately wanting a reversal from 2022's horrible performance. Sizable gains on Friday helped to build more positive sentiment, and the bullish move continued on Monday morning, with the Nasdaq rising 1.5% at midmorning. Big-name companies get the headlines most of the time, but sometimes, news of mergers and acquisitions pushes a little-known company into the spotlight. |
France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, PipelineIpsen (OTC: IPSEY) has agreed to acquire Albireo Pharma Inc (NASDAQ: ALBO) at $42.00 per share in cash for an initial estimated aggregate consideration of $952 million plus one contingent value right (CVR) per share. Each CVR will entitle its holder to deferred cash payments of $10.00 per CVR payable upon the FDA approval of Bylvay in the Biliary Atresia indication at the latest by Dec. 31, 2027. The acquisition of Albireo will provide immediate incremental sales and strengthen Ipsen's rare dise |
We're Not Very Worried About Albireo Pharma's (NASDAQ:ALBO) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |